Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Short term Debt (2016 - 2025)

Immucell (ICCC) has disclosed Short term Debt for 16 consecutive years, with $1.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Short term Debt rose 7.62% year-over-year to $1.6 million, compared with a TTM value of $1.6 million through Sep 2025, up 7.62%, and an annual FY2024 reading of $1.5 million, up 4.82% over the prior year.
  • Short term Debt was $1.6 million for Q3 2025 at Immucell, up from $1.5 million in the prior quarter.
  • Across five years, Short term Debt topped out at $1.6 million in Q3 2025 and bottomed at $767517.0 in Q1 2021.
  • Average Short term Debt over 5 years is $1.2 million, with a median of $1.0 million recorded in 2022.
  • The sharpest move saw Short term Debt fell 25.84% in 2021, then skyrocketed 41.38% in 2023.
  • Year by year, Short term Debt stood at $812207.0 in 2021, then grew by 27.98% to $1.0 million in 2022, then skyrocketed by 37.46% to $1.4 million in 2023, then increased by 4.82% to $1.5 million in 2024, then rose by 6.29% to $1.6 million in 2025.
  • Business Quant data shows Short term Debt for ICCC at $1.6 million in Q3 2025, $1.5 million in Q2 2025, and $1.5 million in Q1 2025.